VivoSim Labs, INC.
VIVSVivoSim Labs, INC. in brief
VivoSim Labs, INC. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $3 M on 20 October 2026, which makes it the 27,328th largest listed company in the world and the 4,455th largest in the USA on this site. In the year to March 2026 it had sales of $0 M and a net loss of $14 M. It employs about 15 people. Its largest product and service lines by sales in 2026 were Royalty (100%). Its shares trade under the symbol VIVS (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About VivoSim Labs, INC.
VivoSim Labs, Inc., is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional human tissue models of liver and intestine. We offer partners liver and intestinal toxicology insights using our new approach methodologies models. We anticipate accelerated adoption of human tissue models following the U.S. Food and Drug Administration announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. We also expect to offer bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of these complex human tissue models.
From the company's annual report filed with the US SEC: read the report
VivoSim Labs, INC. timeline
- 2010
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2011
- ✎Renamed Organovo Holdings, Inc.Formerly Real Estate Restoration & Rental, Inc..
- 2025
- ✎Renamed VivoSim Labs, INC.Formerly Organovo Holdings, Inc..
Events of VivoSim Labs, INC. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,372 (Sep 2026) · #4,457 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 25.0×
- Price / book
- —
- Free cash flow yield
- -333.2%
- Net margin (TTM)
- -7907.7%
- Operating margin
- -8838.5%
- Return on equity
- —
- Liabilities / assets
- 114.7%
- Revenue growth
- -7.1%
- R&D / revenue
- 3223.1%
- Revenue per employee
- $9 K
- Profit per employee
- $-923 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $0M | -7.1% | $-11M | $-14M | -10646.2% |
| Mar 2025 | $0M | +27.3% | $-13M | $-2M | -1778.6% |
| Mar 2024 | $0M | -70.3% | $-15M | $-15M | -13336.4% |
| Mar 2023 | $0M | -75.3% | $-18M | $-17M | -4664.9% |
| Mar 2022 | $2M | — | $-11M | $-11M | -763.3% |
| Mar 2021 | — | — | $-17M | $-17M | — |
| Mar 2020 | $2M | -28.8% | $-21M | $-19M | -850.5% |
| Mar 2019 | $3M | — | $-27M | $-27M | -862.1% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Mar 2026 | $-11M | $0M | $-11M | $-5.35 | — |
| Mar 2025 | $-9M | $0M | $-9M | $-1.70 | — |
| Mar 2024 | $-15M | $0M | $-15M | $-19.25 | — |
| Mar 2023 | $-12M | $0M | $-13M | $-1.98 | — |
| Mar 2022 | $-8M | $0M | $-9M | $-1.32 | — |
| Mar 2021 | $-13M | $0M | $-14M | $-2.44 | — |
| Mar 2020 | $-15M | $0M | $-15M | $-2.80 | — |
| Mar 2019 | $-20M | $0M | $-20M | $-0.23 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $0M (+66.7% on a year earlier), net income $-0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Oct 16, 20268-KCurrent reportMaterial agreement
- Oct 6, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Aug 21, 20268-KCurrent reportListing notice
- Aug 21, 2026DEF 14AProxy statement
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jul 31, 2026S-1IPO registration
- Jul 30, 20268-KCurrent reportOther events
- Jul 24, 20268-KCurrent reportListing notice · Other events
- Jul 17, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Other events
- Jul 14, 202610-KAnnual report · period to Mar 2026
Official filings of VivoSim Labs, INC. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-11 M
- Net income
- $-14 M
For year ending March-2026 · source: SEC filing
Balance sheet
- Total assets
- $7 M
- Total liabilities
- $8 M
- Total equity
- $-1 M
As of March-2026
Top 27 institutional investors in VivoSim Labs, INC.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 390,431 | New | 1.93% | $0 M | Nov 16, 2026 |
| 2 | Jane Street Group, LLC | 46,986 | New | 0.23% | $0 M | Nov 12, 2026 |
| 3 | Geode Capital Management, LLC | 20,173 | -5,803 (-22.34%) | 0.10% | $0 M | Nov 6, 2026 |
| 4 | Vanguard Capital Management LLC | 15,371 | 0 (0.00%) | 0.08% | $0 M | Nov 13, 2026 |
| 5 | TRUE Private Wealth Advisors | 10,895 | New | 0.05% | $0 M | Oct 19, 2026 |
| 6 | BlackRock, Inc. | 10,342 | -1,475 (-12.48%) | 0.05% | $0 M | Nov 13, 2026 |
| 7 | UBS Group AG | 9,118 | +9,100 (+50555.56%) | 0.04% | $0 M | Nov 10, 2026 |
| 8 | Vanguard Fiduciary Trust Co | 7,003 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 9 | Tower Research Capital LLC (TRC) | 6,021 | +772 (+14.71%) | 0.03% | $0 M | Nov 16, 2026 |
| 10 | Allworth Financial LP | 500 | New | 0.00% | $0 M | Nov 17, 2026 |
| 11 | SBI Securities Co., Ltd. | 221 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 12 | Larson Financial Group LLC | 166 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 13 | Albion Financial Group /ut | 159 | 0 (0.00%) | 0.00% | $0 M | Oct 21, 2026 |
| 14 | Wells Fargo & Company/mn | 136 | +25 (+22.52%) | 0.00% | $0 M | Nov 16, 2026 |
| 15 | Osaic Holdings, Inc. | 92 | +8 (+9.52%) | 0.00% | $0 M | Nov 12, 2026 |
| 16 | Robinhood Markets, Inc. | 42 | — | 0.00% | $0 M | Nov 18, 2026 |
| 17 | Morgan Stanley | 41 | -8 (-16.33%) | 0.00% | $0 M | Nov 13, 2026 |
| 18 | IFG Advisory, LLC | 14 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 19 | Jones Financial Companies Lllp | 8 | New | 0.00% | $0 M | Nov 13, 2026 |
| 20 | Pinnacle Financial Group, Inc. | 6 | — | 0.00% | $0 M | Nov 16, 2026 |
| 21 | Rockefeller Capital Management L.P. | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 22 | Golden State Wealth Management, LLC | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 2, 2026 |
| 23 | Activest Wealth Management | 2 | 0 (0.00%) | 0.00% | $0 M | Oct 15, 2026 |
| 24 | Harbour Investments, Inc. | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 25 | Royal Bank Of Canada | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
Show all 27: investors 26 to 27
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Caitong International Asset Management Co., Ltd | 1 | -16 (-94.12%) | 0.00% | $0 M | Oct 29, 2026 |
| 27 | Hilton Head Capital Partners, LLC | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 23, 2026 |
Mutual funds holding VivoSim Labs, INC.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 24,544 | $0 M | 0.12% | <0.01% | +11% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 15,371 | $0 M | 0.08% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 4,055 | $0 M | 0.02% | <0.01% | +126% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 991 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at VivoSim Labs, INC.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Tony Serge LialinChief Commercial Officer | Buy | +10,000 | $0.280 | $3 K | 10,000 | Form 4 |
| filed | Adam K. SternDirector | Grant or award | +15,000 | — | — | 19,899 | Form 4 |
| filed | Douglas Jay CohenDirector | Grant or award | +15,000 | — | — | 20,732 | Form 4 |
| filed | David GobelDirector | Grant or award | +15,000 | — | — | 15,000 | Form 4 |
| filed | Alison Tjosvold MilhousDirector | Grant or award | +15,000 | — | — | 19,899 | Form 4 |
| filed | Keith MurphyEXECUTIVE CHAIRMAN, Director | Grant or award | +15,000 | — | — | 26,053 | Form 4 |
| filed | David GobelDirector | Sell | +3,266 | $2.240 | $7 K | 0 | Form 4 |
| filed | Vaidehi JoshiDirector | Grant or award | +19,607 | — | — | 58,821 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: VivoSim Labs, INC.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-12 reverse split in the period to ; 20-for-1 split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q1 2022 | Q4 2022 | $0M |
| Q4 2021 | Q3 2022 | $0M |
| Q1 2021 | Q4 2021 | $0M |
| Q4 2020 | Q3 2021 | $0M |
| Q1 2020 | Q4 2021 | $0M |
| Q4 2019 | Q3 2021 | $0M |
Trading halts
- 2026-07-15 13:34 UTC, code LUDP, resumed 13:39 UTC
Fails to deliver
- : 27,406 shares at $0.16
- : 47,179 shares at $0.16
- : 67,128 shares at $0.17
- : 8,396 shares at $0.20
- : 31,594 shares at $0.26
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
VivoSim Labs, INC. scorecard#
Passes 2 of the 12 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 20, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✗Price to sales below its peers' median25.0×Price to sales 25.0× against Biotechnology's median of 8.7×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-5.35 vs -1.70Diluted EPS -5.35 in fiscal 2025 against -1.70 the year before (report's currency).
- ✓Net income higher than five years earlier-$14 M-$14 M in fiscal 2025 against -$17 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$14 MNet income -$14 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.38 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-71.70Z-score -71.70 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year76.8%Diluted shares up 76.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
VivoSim Labs, INC.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Mar 31, 2026 | FY 2024to Mar 31, 2025 | FY 2023to Mar 31, 2024 | FY 2022to Mar 31, 2023 | FY 2021to Mar 31, 2022 | FY 2020to Mar 31, 2021 | FY 2019to Mar 31, 2020 | FY 2018to Mar 31, 2019 | FY 2017to Mar 31, 2018 | FY 2016to Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.1−9.0%100% | 0.1+32.1%100% | 0.1−70.5%100% | 0.4−75.3%100% | 1.5—100% | 0−100%— | 2.2−29.0%100% | 3.1−32.8%100% | 4.6+8.8%100% | 4.2—100% | |
| Cost of revenue | 0−100%0.0% | 0.0—3.5% | — | — | — | 0−100%— | 0.3−40.0%13.7% | 0.5−50.0%16.2% | 1.0r1.0+4.6%21.7% | 1.0—22.6% | |
| Research and development | 4.2−16.6%3198% | 5.0−8.6%3490% | 5.5−38.1%5044% | 8.9+168%2401% | 3.3+201%221% | 1.1−79.1%— | 5.3−64.2%241% | 15−17.8%477% | 18−8.1%390% | 20—462% | |
| Selling, general and administrative | 7.4−3.9%5671% | 7.7−20.3%5368% | 9.7+5.2%8896% | 9.2−4.6%2491% | 9.7−38.6%644% | 16−12.9%— | 18+19.4%822% | 15−27.6%490% | 21−6.3%454% | 22—527% | |
| Total costs and expenses | 12−8.9%8869% | 13−16.0%8861% | 15−16.1%13940% | 18+39.5%4892% | 13−22.9%865% | 17−28.9%— | 24−22.0%1078% | 30−23.8%982% | 40−6.8%866% | 43—1012% | |
| Operating income | −11—−8769% | −13—−8761% | −15—−13840% | −18—−4792% | −11—−765% | −17—— | −21—−978% | −27—−882% | −35—−766% | −39—−912% | |
| Interest and finance income | 0.3+90.7%204% | 0.1−65.4%97.2% | 0.4−10.8%372% | 0.5+5575%123% | 0.0−46.7%0.5% | 0.0−97.5%— | 0.6−15.7%27.0% | 0.7+47.5%22.8% | 0.5+141%10.4% | 0.2—4.7% | |
| Interest expense and finance costs | 0.0+20.0%9.2% | 0.0—6.9% | — | — | — | — | — | — | — | 0—0.0% | |
| Other non-operating income (expense) | −2.4−123%−1797% | 10+2329%7035% | 0.4−12.0%383% | 0.5+1336%128% | 0.0+1550%2.2% | 0.0−99.9%— | 2.8+331%126% | 0.6+36.6%20.8% | 0.5+211%10.2% | 0.2—3.6% | |
| Income before tax | −14—−10566% | −2.5—−1726% | — | — | — | — | — | — | — | — | |
| Income tax | 0.00.0%1.5% | 0.00.0%1.4% | 0.00.0%1.8% | 0.00.0%0.5% | 0.00.0%0.1% | 0.00.0%— | 0.0−33.3%0.1% | 0.0+50.0%0.1% | 0.0−91.3%0.0% | 0.0—0.5% | |
| Net income including minority interests | −14—−10567% | −2.5—−1728% | −15—−13460% | −17—−4665% | −11—−763% | −17—— | −19—−852% | −27—−862% | −35—−756% | −38—−909% | |
| Net income attributable to shareholders | −14—−10567% | −2.5—−1728% | −15—−13460% | −17—−4665% | −11—−763% | −17—— | −19—−852% | −27—−862% | −35—−756% | −38—−909% | |
| Earnings per share, basic | -5.35—— | -1.70—— | -19.25r-1.60—— | -1.98—— | -1.32—— | -2.44—— | -2.80r-0.14—— | -0.23—— | -0.32—— | -0.39—— | |
| Earnings per share, diluted | -5.35—— | -1.70—— | -19.25r-1.60—— | -1.98—— | -1.32—— | -2.44—— | -2.80r-0.14—— | -0.23—— | -0.32—— | -0.39—— | |
| Shares, weighted average (basic) | 2.6+76.8%— | 1.5+92.1%— | 0.8r9.1−91.3%— | 8.7+0.1%— | 8.7—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 2.6+76.8%— | 1.5+92.1%— | 0.8r9.1−91.3%— | 8.7+0.1%— | 8.7+26.1%— | 6.9+6.5%— | 6.5r130−94.4%— | 115+7.6%— | 107+9.7%— | 98—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 5.0−55.6%68.0% | 11+290%77.2% | 2.9−81.0%45.7% | 15−46.6%75.3% | 29−23.3%86.1% | 37+36.6%93.6% | 27−25.0%96.2% | 36−16.6%89.8% | 44−30.3%87.8% | 63—90.7% | |
| Short-term investments | — | — | — | — | 0—0.0% | — | — | — | — | — | |
| Receivables | 0.0+6.7%0.4% | 0.0−9.1%0.2% | 0.0−78.3%0.5% | 0.2—0.7% | 0—0.0% | 0−100%0.0% | 0.1−77.9%0.4% | 0.5−43.0%1.2% | 0.9+36.5%1.8% | 0.6—0.9% | |
| Inventory | 0—0.0% | 0−100%0.0% | 0.3—4.7% | 0—0.0% | — | — | 0−100%0.0% | 0.5−41.8%1.2% | 0.8+53.1%1.7% | 0.6—0.8% | |
| Other current assets | 0−100%0.0% | 0.0r0.0+200%0.1% | 0.0r0.0−94.2%0.1% | 0.1r0.9−92.0%0.3% | 0.9−17.0%2.6% | 1.0+21.5%2.6% | 0.9−18.9%3.0% | 1.0−9.9%2.6% | 1.2+1.7%2.3% | 1.1—1.7% | |
| Current assets | 6.6−45.4%89.7% | 12+208%82.8% | 3.9−76.9%62.0% | 17−42.3%83.9% | 30−23.1%88.7% | 38+35.6%96.2% | 28−26.6%99.6% | 39−17.5%95.0% | 47−28.2%93.8% | 65—94.1% | |
| Property, plant and equipment | 0.2−50.8%2.8% | 0.4−37.4%2.9% | 0.7−25.8%10.5% | 0.9+36.3%4.4% | 0.7+73.8%2.0% | 0.4—1.0% | 0−100%0.0% | 1.8−34.3%4.5% | 2.8−27.4%5.6% | 3.8—5.6% | |
| Right-of-use (leased) assets | 0.4−53.1%5.5% | 0.9−33.3%5.9% | 1.3−23.8%20.5% | 1.7−20.8%8.4% | 2.2—6.5% | 0—0.0% | — | 0r4.5—0.0% | — | — | |
| Total assets | 7.4−49.6%100% | 15+131%100% | 6.3−68.7%100% | 20−39.0%100% | 33−16.6%100% | 40+40.4%100% | 28−30.0%100% | 41−18.5%100% | 50−28.0%100% | 69—100% | |
| Accounts payable | 1.0−37.9%13.8% | 1.6+162%11.2% | 0.6+89.4%9.9% | 0.3−20.2%1.6% | 0.4+47.7%1.2% | 0.3−61.0%0.7% | 0.7+14.6%2.5% | 0.6+35.3%1.5% | 0.5−60.4%0.9% | 1.2—1.7% | |
| Current liabilities | 2.8−25.5%37.7% | 3.7+101%25.5% | 1.9−49.3%29.3% | 3.7+165%18.1% | 1.4+91.8%4.2% | 0.7−60.2%1.8% | 1.8−51.6%6.4% | 3.7−19.8%9.2% | 4.7−22.5%9.3% | 6.0—8.7% | |
| Lease liabilities (non-current) | 0−100%0.0% | 0.4−52.6%2.9% | 0.9−32.4%14.0% | 1.3−22.9%6.5% | 1.7—5.1% | 0—0.0% | — | 0—0.0% | — | — | |
| Total liabilities | 8.5+104%115% | 4.2+51.3%28.4% | 2.7−44.9%43.3% | 5.0+61.5%24.5% | 3.1+328%9.3% | 0.7−60.2%1.8% | 1.8−58.2%6.4% | 4.3−17.5%10.6% | 5.2−23.1%10.5% | 6.8—9.9% | |
| Retained earnings | −356—−4820% | −342—−2336% | −340—−5350% | −325—−1600% | −308—−924% | −296—−742% | −279—−983% | −261—−642% | −234—−470% | −199—−288% | |
| Shareholders' equity | −1.1−110%−14.9% | 10+191%71.6% | 3.6−76.5%56.7% | 15−49.3%75.5% | 30−22.9%90.7% | 39+47.2%98.2% | 27−26.6%93.6% | 36−18.6%89.4% | 45−28.5%89.5% | 62—90.1% | |
| Total equity | −1.1−110%−14.9% | 10+191%71.6% | 3.6−76.5%56.7% | 15−49.3%75.5% | 30−22.9%90.7% | 39+47.2%98.2% | 27−26.6%93.6% | 36−18.6%89.4% | 45−28.5%89.5% | 62—90.1% | |
| Total liabilities and equity | 7.4−49.6%100% | 15+131%100% | 6.3−68.7%100% | 20−39.0%100% | 33−16.6%100% | 40+40.4%100% | 28−30.0%100% | 41−18.5%100% | 50−28.0%100% | 69—100% | |
| Shares outstanding | 2.9+52.5%— | 1.9+126%— | 0.8r10−90.4%— | 8.7+0.1%— | 8.7+0.5%— | 8.7+32.8%— | 6.5r131−94.7%— | 124+11.7%— | 111+6.2%— | 105—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.2−19.2%164% | 0.3−5.0%185% | 0.3−4.4%257% | 0.3+106%79.2% | 0.1+246%9.5% | 0.0−96.4%— | 1.1+16.5%52.0% | 1.0−22.7%31.7% | 1.3+10.3%27.5% | 1.1—27.2% | |
| Share-based compensation | 0.3−43.0%231% | 0.5−64.7%369% | 1.5−36.6%1383% | 2.4+5.4%642% | 2.3−59.4%150% | 5.6+35.2%— | 4.1−20.9%187% | 5.2−24.8%168% | 6.9−6.6%150% | 7.4—175% | |
| Cash from operating activities | −11—−8265% | −9.5—−6570% | −15—−13443% | −12—−3354% | −8.5—−564% | −13—— | −15—−678% | −20—−659% | −29—−627% | −29—−690% | |
| Capital expenditure | 0—0.0% | −0.0—−9.0% | −0.0—−38.5% | −0.4—−107% | −0.4—−27.3% | −0.4—— | 0—0.0% | −0.1—−2.6% | −0.2—−4.9% | −1.4—−32.0% | |
| Intangible assets bought | — | — | — | — | — | — | — | 0—0.0% | −0.1—−1.5% | 0—0.0% | |
| Cash from investing activities | 0.1−99.0%71.8% | 9.0+1006%6267% | 0.8—749% | −1.0—−261% | −0.4—−27.3% | −0.4−153%— | 0.7—34.0% | −0.1—−2.5% | −0.3—−6.3% | −1.4—−32.9% | |
| Shares issued | 4.8−45.7%3670% | 8.8+516%6144% | 1.4—1318% | 0−100%0.0% | 0.3−98.9%16.7% | 24+376%— | 5.0−62.5%228% | 13+42.1%431% | 9.4—204% | — | |
| Shares bought back | — | — | — | — | 0—0.0% | −0.0—— | 0—0.0% | — | — | — | |
| Cash from financing activities | 4.4−49.8%3393% | 8.8+516%6144% | 1.4—1318% | 0−100%0.0% | 0.2−99.1%13.7% | 24+383%— | 4.9−62.5%225% | 13+30.1%426% | 10−67.6%220% | 31—739% | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | — | 0.0—0.2% | −0.0—−0.3% | |
| Change in cash | −6.3−175%−4800% | 8.4—5841% | −12—−11376% | −13—−3615% | −8.7−186%−577% | 10—— | −9.2—−419% | −7.3—−236% | −19−2983%−413% | 0.7—15.6% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q2 FY2026to Sep 30, 2026 | Q1 FY2026to Jun 30, 2026 | Q4 FY2025to Mar 31, 2026 | Q3 FY2025to Dec 31, 2025 | Q2 FY2025to Sep 30, 2025 | Q1 FY2025to Jun 30, 2025 | Q4 FY2024to Mar 31, 2025 | Q3 FY2024to Dec 31, 2024 | Q2 FY2024to Sep 30, 2024 | Q1 FY2024to Jun 30, 2024 | Q4 FY2023to Mar 31, 2024 | Q3 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0.1−3.6%100% | 0.1+82.1%100% | 0.0−51.4%100% | 0.0*−21.6%100% | 0.0+8.3%100% | 0.0−6.7%100% | 0.0−5.1%100% | 0.1*+75.9%100% | 0.0+380%100% | 0.0—100% | 0.0—100% | 0.0*—100% | 0.0—100% | |
| Cost of revenue | — | 0.1—110% | — | 0*—0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0*—0.0% | 0.0—8.3% | 0.0—3.3% | 0.0—5.1% | — | 0—0.0% | |
| Research and development | 4.5−1.5%3328% | 1.1+18.7%2149% | 1.1+13.1%6289% | 1.1*+31.0%2813% | 1.1−36.0%4385% | 0.9−6.2%3296% | 1.0−28.6%2705% | 0.9*−19.2%1684% | 1.8+24.1%7417% | 1.0—3280% | 1.4—3595% | 1.1*—3666% | 1.4—28680% | |
| Selling, general and administrative | 7.6−1.9%5628% | 2.2+27.3%4343% | 1.6−15.7%9139% | 2.1*−10.4%5255% | 1.6−4.3%6292% | 1.7+5.3%6214% | 2.0−3.5%5273% | 2.3*+13.8%4600% | 1.7−24.0%7125% | 1.7—5510% | 2.0—5182% | 2.1*—7110% | 2.3—45020% | |
| Total costs and expenses | 12−1.3%8998% | 3.4+26.4%6602% | 2.8−5.9%15428% | 3.2*+0.7%8068% | 2.8−20.5%10677% | 2.7+0.9%9511% | 3.0−13.8%7978% | 3.2*+2.6%6284% | 3.5−5.2%14550% | 2.6—8793% | 3.4—8782% | 3.1*—10776% | 3.7—73700% | |
| Operating income | −12—−8898% | −3.3—−6502% | −2.8—−15328% | −3.2*—−7968% | −2.8—−10577% | −2.6—−9411% | −2.9—−7878% | −3.2*—−6184% | −3.5—−14450% | −2.6—−8693% | −3.4—−8682% | −3.1*—−10676% | −3.7—−73600% | |
| Interest and finance income | 0.2−11.7%134% | 0.1−41.3%106% | 0.0−63.2%156% | 0.0*+227%90.0% | 0.1+142%242% | 0.1+55.9%329% | 0.1+72.7%205% | 0.0*−78.4%21.6% | 0.0−65.8%108% | 0.1—197% | 0.0—113% | 0.1*—176% | 0.1—1520% | |
| Interest expense and finance costs | 0.0−14.3%8.9% | 0—0.0% | 0.00.0%22.2% | 0.0*−20.0%10.0% | 0.0−20.0%15.4% | 0—0.0% | 0.0—10.8% | 0.0*—9.8% | 0.0—20.8% | 0—0.0% | 0—0.0% | — | 0—0.0% | |
| Other non-operating income (expense) | 1.7−82.9%1294% | 2.8+2988%5571% | 1.4+1878%7911% | −2.6*−126%−6443% | 0.1+181%227% | 0.1+55.9%329% | 0.1+63.6%195% | 10*+19520%19620% | 0.0−72.4%87.5% | 0.1—197% | 0.0—113% | 0.1*—176% | 0.1—1520% | |
| Income tax | 0.0+50.0%2.2% | 0−100%0.0% | 0.0—16.7% | 0*—0.0% | 0—0.0% | 0.0—7.1% | 0−100%0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | 0.0—5.1% | 0*—0.0% | 0—0.0% | |
| Net income including minority interests | −10—−7606% | −0.5—−931% | −1.3—−7433% | −5.8*−184%−14410% | −2.7—−10350% | −2.5—−9089% | −2.8—−7684% | 6.9*—13435% | −3.4—−14363% | −2.5—−8497% | −3.3—−8574% | −3.0*—−10500% | −3.6—−72080% | |
| Net income attributable to shareholders | −10—−7606% | −0.5—−931% | −1.3—−7433% | −5.8*−184%−14410% | −2.7—−10350% | −2.5—−9089% | −2.8—−7684% | 6.9*—13435% | −3.4—−14363% | −2.5—−8497% | −3.3—−8574% | −3.0*—−10500% | −3.6—−72080% | |
| Earnings per share, basic | — | -0.03—— | -0.25—— | — | -1.03—— | -0.98—— | -1.14—— | — | -2.28r-0.19—— | -1.68r-0.14—— | -2.74r-0.23—— | — | -0.40—— | |
| Earnings per share, diluted | — | -0.03—— | -0.25—— | — | -1.03—— | -0.98—— | -1.14—— | — | -2.28r-0.19—— | -1.68r-0.14—— | -2.74r-0.23—— | — | -0.40—— | |
| Shares, weighted average (basic) | 16+531%— | 16+531%— | 5.2+109%— | — | 2.6+73.3%— | 2.6+73.7%— | 2.5+105%— | — | 1.5r18−83.5%— | 1.5r18—— | 1.2r15—— | — | 9.1—— | |
| Shares, weighted average (diluted) | 16+531%— | 16+531%— | 5.2+109%— | — | 2.6+73.3%— | 2.6+73.7%— | 2.5+105%— | — | 1.5r18−83.5%— | 1.5r18—— | 1.2r15—— | — | 9.1—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 8.6—86.3% | 8.6+28.3%86.3% | 1.7−81.6%43.4% | 5.0−55.6%68.0% | 4.3+269%61.6% | 6.7+110%68.9% | 9.1+46.4%75.6% | 11+290%77.2% | 1.2−78.1%30.2% | 3.2—47.0% | 6.2—65.3% | 2.9—45.7% | 5.3—59.6% | |
| Receivables | 0.1—0.6% | 0.1+75.0%0.6% | 0.0−9.4%0.8% | 0.0+6.7%0.4% | 0.0+26.9%0.5% | 0.0+10.3%0.3% | 0.0−33.3%0.3% | 0.0−9.1%0.2% | 0.0−21.2%0.7% | 0.0—0.4% | 0.0—0.5% | 0.0—0.5% | 0.0—0.4% | |
| Inventory | 0.0—0.3% | 0.0—0.3% | — | 0—0.0% | — | — | — | 0−100%0.0% | 0—0.0% | 0.6—9.5% | 0.4—4.3% | 0.3—4.7% | — | |
| Other current assets | 0.7—7.5% | 0.7−15.3%7.5% | 0.5−13.7%13.3% | 0−100%0.0% | 0.7−22.3%10.2% | 0.9−6.2%9.1% | 0.6−7.5%4.9% | 0.0r0.0+200%0.1% | 0.90.0%23.8% | 0.9—13.9% | 0.6—6.8% | 0.0r0.0—0.1% | 0.9—10.3% | |
| Current assets | 9.4—94.7% | 9.4+23.8%94.7% | 3.2−66.7%83.9% | 6.6−45.4%89.7% | 6.0+188%86.8% | 7.6+58.7%78.4% | 9.7+32.9%80.8% | 12+208%82.8% | 2.1−66.4%54.6% | 4.8—70.8% | 7.3—76.9% | 3.9—62.0% | 6.2—70.3% | |
| Property, plant and equipment | 0.2—2.2% | 0.2−27.7%2.2% | 0.2−47.4%4.9% | 0.2−50.8%2.8% | 0.2−48.2%3.6% | 0.3−45.0%3.1% | 0.4−40.3%3.0% | 0.4−37.4%2.9% | 0.5−35.2%12.5% | 0.5—8.1% | 0.6—6.3% | 0.7—10.5% | 0.7—8.3% | |
| Right-of-use (leased) assets | 0.2—1.7% | 0.2−74.3%1.7% | 0.3−62.0%7.5% | 0.4−53.1%5.5% | 0.5−46.3%7.5% | 0.6−41.0%6.6% | 0.8−36.8%6.3% | 0.9−33.3%5.9% | 1.0−30.3%25.4% | 1.1—16.1% | 1.2—12.6% | 1.3—20.5% | 1.4—15.8% | |
| Total assets | 9.9—100% | 9.9+2.5%100% | 3.8−67.9%100% | 7.4−49.6%100% | 7.0+81.1%100% | 9.7+43.4%100% | 12+26.5%100% | 15+131%100% | 3.8−56.7%100% | 6.8—100% | 9.5—100% | 6.3—100% | 8.9—100% | |
| Accounts payable | 1.0—9.6% | 1.0+64.3%9.6% | 0.6−7.7%16.1% | 1.0−37.9%13.8% | 0.7−27.8%9.6% | 0.6+38.4%6.0% | 0.7−39.9%5.6% | 1.6+162%11.2% | 0.9+97.5%24.2% | 0.4—6.2% | 1.1—11.8% | 0.6—9.9% | 0.5—5.3% | |
| Current liabilities | 2.7—27.0% | 2.7+9.5%27.0% | 1.9−11.6%49.2% | 2.8−25.5%37.7% | 2.5−15.7%35.6% | 2.4+1.4%25.3% | 2.1+5.4%17.9% | 3.7+101%25.5% | 2.9+72.8%76.4% | 2.4—35.7% | 2.0—21.5% | 1.9—29.3% | 1.7—19.1% | |
| Lease liabilities (non-current) | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0.0−91.9%0.6% | 0.2−73.9%1.8% | 0.3−61.5%2.5% | 0.4−52.6%2.9% | 0.5−45.6%14.1% | 0.7—9.8% | 0.8—8.2% | 0.9—14.0% | 1.0—11.2% | |
| Total liabilities | 2.7—27.0% | 2.7+2.3%27.0% | 6.2+154%161% | 8.5+104%115% | 2.5−27.6%36.2% | 2.6−14.7%27.1% | 2.4−13.1%20.4% | 4.2+51.3%28.4% | 3.5+28.9%90.5% | 3.1—45.5% | 2.8—29.7% | 2.7—43.3% | 2.7—30.4% | |
| Retained earnings | −358—−3606% | −358—−3606% | −357—−9289% | −356—−4820% | −350—−5032% | −348—−3588% | −345—−2880% | −342—−2336% | −349—−9079% | −346—−5116% | −343—−3622% | −340—−5350% | −337—−3790% | |
| Shareholders' equity | 7.2—73.0% | 7.2+2.5%73.0% | −2.3−125%−61.0% | −1.1−110%−14.9% | 4.4+1120%63.8% | 7.1+92.0%72.9% | 9.5+43.2%79.6% | 10+191%71.6% | 0.4−94.1%9.5% | 3.7—54.5% | 6.7—70.3% | 3.6—56.7% | 6.2—69.6% | |
| Total equity | 7.2—73.0% | 7.2+2.5%73.0% | −2.3−125%−61.0% | −1.1−110%−14.9% | 4.4+1120%63.8% | 7.1+92.0%72.9% | 9.5+43.2%79.6% | 10+191%71.6% | 0.4−94.1%9.5% | 3.7—54.5% | 6.7—70.3% | 3.6—56.7% | 6.2—69.6% | |
| Total liabilities and equity | 9.9—100% | 9.9+2.5%100% | 3.8−67.9%100% | 7.4−49.6%100% | 7.0+81.1%100% | 9.7+43.4%100% | 12+26.5%100% | 15+131%100% | 3.8−56.7%100% | 6.8—100% | 9.5—100% | 6.3—100% | 8.9—100% | |
| Shares outstanding | 18—— | 18+593%— | 3.2+22.9%— | 2.9+52.5%— | 2.6−84.8%— | 2.6−83.0%— | 2.6−81.9%— | 1.9+126%— | 17+74.1%— | 15—— | 14—— | 0.8r10—— | 9.8—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.2−31.5%126% | 0.0*−40.7%68.6% | 0.0−34.4%222% | 0.0*−29.5%108% | 0.1*−22.4%200% | 0.1*−13.2%211% | 0.1−12.9%165% | 0.1*−14.1%120% | 0.1*−5.6%279% | 0.1*—227% | 0.1—179% | 0.1*—245% | 0.1*—1420% | |
| Share-based compensation | 0.5+29.1%355% | 0.2+226%461% | 0.1+16.7%506% | 0.1*−5.5%215% | 0.1−48.5%258% | 0.1−53.5%257% | 0.1−50.0%211% | 0.1*−54.7%178% | 0.1−17.2%542% | 0.2—517% | 0.2—400% | 0.2*—693% | 0.2—3140% | |
| Cash from operating activities | −10—−7556% | −2.5*—−4859% | −3.2—−17850% | −2.2*—−5595% | −2.3*—−8735% | −2.4*—−8493% | −3.9—−10649% | −2.0*—−3990% | −1.8*—−7504% | −2.6*—−8807% | −3.0—−7649% | −2.7*—−9210% | −3.5*—−70440% | |
| Capital expenditure | −0.1—−63.0% | −0.1*—−122% | −0.0—−128% | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | −0.0*—−43.3% | 0—0.0% | 0*—0.0% | 0*—0.0% | |
| Cash from investing activities | 6.0−33.1%4461% | 6.0*—11671% | −0.0—−128% | 0.1*−99.0%235% | 0*−100%0.0% | 0*—0.0% | 0−100%0.0% | 9.0*+69138%17649% | 0.0*−85.2%16.7% | 0*—0.0% | 0.0—51.3% | 0.0*—44.8% | 0.0*—540% | |
| Shares issued | 3.0−37.2%2222% | 0.0*—5.9% | 0−100%0.0% | 3.0*−5.9%7493% | 0*—0.0% | 0*—0.0% | 1.8−71.0%4895% | 3.2*+1106%6245% | −0.2*−118%−900% | −0.4*—−1237% | 6.2—16023% | 0.3*—910% | 1.2*—23460% | |
| Cash from financing activities | 6.1+30.4%4492% | 3.4*—6706% | −0.1−107%−656% | 2.9*−9.6%7200% | −0.1*—−454% | 0*—0.0% | 1.7−73.1%4549% | 3.2*+1106%6245% | −0.2*−118%−900% | −0.4*—−1237% | 6.2—16023% | 0.3*—910% | 1.2*—23460% | |
| Change in cash | 1.9−46.1%1398% | 6.9*—13518% | −3.4—−18633% | 0.7*−92.7%1840% | −2.4*—−9188% | −2.4*—−8493% | −2.3−169%−6100% | 10*—19904% | −2.0*—−8388% | −3.0*—−10043% | 3.3—8426% | −2.4*—−8255% | −2.3*—−46440% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What VivoSim Labs, INC. sells: revenue by product line, fiscal 2026#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Royalty$0 M100%+8.3%
Source: SEC annual report (XBRL data) · as of Mar 31, 2026
Executive pay at VivoSim Labs, INC.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2026Mr. Murphy | $866 K | $780 K | $218 K | $1 |
| 2025Mr. Murphy | $1.2 M | $888 K | $136 K | $2 |
| 2024Mr. Murphy | $681 K | $596 K | $343 K | $11 |
Source: SEC proxy statement (Form DEF 14A) · as of Mar 31, 2026
Events at VivoSim Labs, INC.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 4 · Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 4 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 2
| Filed | What happened | Filing |
|---|---|---|
| Material agreement | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Acquisition or sale completedDirectors and officers | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Delisting noticeMaterial agreement | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 16, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2012 | $8 M | Issued in a merger or acquisition | $2 to $10 million | 119 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by VivoSim Labs, INC.#
$70 K spent on lobbying the US Congress and federal agencies in 2026, most often on health issues.
- Health Issues3 reports
Lobbying firms hired in 2026
TSG ADVOCATES DC, LLC $70 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $70 K | — | 3 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “VivoSim Labs, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2017 | · | · | · | · | · | · | · | · | 15 | · | · | · | 15 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 24% of workforce | Restructuring planSEC 8-K | “As previously disclosed in the Original Report, on August 18, 2023, the Company announced to its employees a plan to reduce the Company’s workforce, effective August 25, 2023, by a…” | Filing | |
| 24% of workforce | Restructuring planSEC 8-K | “(the “Company”) announced to its employees a plan to reduce the Company’s workforce, effective August 25, 2023, by approximately six employees, which represents approximately 24% o…” | Filing | |
| 15 people | Restructuring planSEC 8-K | “Under this plan, which is expected to be completed in November 2017, the Company will reduce its overall workforce by 15 employees (or 13%).” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How VivoSim Labs, INC. compares in Biotechnology
- Market cap$3 M · higher than 3% of 726
- Revenue$0 M · higher than 17% of 647
- Revenue growth-7.1% · higher than 36% of 438
- Price / sales25.0× · lower than 28% of 339
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| VivoSim Labs, INC.🇺🇸 | $3 M | — | — | -7.1% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 20, 2026
- Annual results:
- For year ending March-2026
- Balance sheet:
- As of March-2026
- Employees:
- As of June 1, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at VivoSim Labs, INC.? Verify and update this profile — free
Show VivoSim Labs, INC.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.